Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a cash flow conversion efficiency ratio of -0.212x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-19.96 Million ≈ $-2.92 Million USD) by net assets (CN¥94.30 Million ≈ $13.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hangzhou TianMuShan Pharmaceutical Enter debt and liabilities for a breakdown of total debt and financial obligations.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enento Group Plc
HE:ENENTO
|
0.057x |
|
Nano Dimension Ltd
NASDAQ:NNDM
|
-0.020x |
|
Hiper Global Ltd
TA:HIPR
|
0.127x |
|
DIAMOND BIOFUND INC
TW:6901
|
-0.002x |
|
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
|
0.001x |
|
Adlai Nortye Ltd. American Depositary Shares
NASDAQ:ANL
|
-1.791x |
|
AB Traction
ST:TRAC-B
|
0.030x |
|
Pollard Banknote Limited
TO:PBL
|
0.102x |
Annual Cash Flow Conversion Efficiency for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Hangzhou TianMuShan Pharmaceutical Enter (600671) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥85.02 Million ≈ $12.44 Million |
CN¥-36.67 Million ≈ $-5.37 Million |
-0.431x | -18.14% |
| 2023-12-31 | CN¥55.95 Million ≈ $8.19 Million |
CN¥-20.43 Million ≈ $-2.99 Million |
-0.365x | +91.56% |
| 2022-12-31 | CN¥4.48 Million ≈ $655.53K |
CN¥-19.37 Million ≈ $-2.83 Million |
-4.324x | -956.52% |
| 2021-12-31 | CN¥64.56 Million ≈ $9.45 Million |
CN¥-26.42 Million ≈ $-3.87 Million |
-0.409x | -354.96% |
| 2020-12-31 | CN¥93.33 Million ≈ $13.66 Million |
CN¥-8.40 Million ≈ $-1.23 Million |
-0.090x | -107.44% |
| 2019-12-31 | CN¥133.33 Million ≈ $19.51 Million |
CN¥161.13 Million ≈ $23.58 Million |
1.209x | +39.51% |
| 2018-12-31 | CN¥81.62 Million ≈ $11.94 Million |
CN¥70.71 Million ≈ $10.35 Million |
0.866x | +240.09% |
| 2017-12-31 | CN¥96.27 Million ≈ $14.09 Million |
CN¥24.52 Million ≈ $3.59 Million |
0.255x | +949.12% |
| 2016-12-31 | CN¥66.18 Million ≈ $9.68 Million |
CN¥1.61 Million ≈ $235.13K |
0.024x | +203.93% |
| 2015-12-31 | CN¥62.76 Million ≈ $9.18 Million |
CN¥-1.47 Million ≈ $-214.52K |
-0.023x | -404.59% |
| 2014-12-31 | CN¥85.25 Million ≈ $12.47 Million |
CN¥653.79K ≈ $95.67K |
0.008x | -94.10% |
| 2013-12-31 | CN¥95.26 Million ≈ $13.94 Million |
CN¥12.37 Million ≈ $1.81 Million |
0.130x | +160.78% |
| 2012-12-31 | CN¥92.76 Million ≈ $13.57 Million |
CN¥-19.82 Million ≈ $-2.90 Million |
-0.214x | -501.81% |
| 2011-12-31 | CN¥182.84 Million ≈ $26.75 Million |
CN¥-6.49 Million ≈ $-950.05K |
-0.036x | +56.56% |
| 2010-12-31 | CN¥154.14 Million ≈ $22.55 Million |
CN¥-12.60 Million ≈ $-1.84 Million |
-0.082x | -302.37% |
| 2009-12-31 | CN¥187.74 Million ≈ $27.47 Million |
CN¥7.58 Million ≈ $1.11 Million |
0.040x | -54.19% |
| 2008-12-31 | CN¥240.30 Million ≈ $35.16 Million |
CN¥21.19 Million ≈ $3.10 Million |
0.088x | -47.51% |
| 2007-12-31 | CN¥282.93 Million ≈ $41.40 Million |
CN¥47.53 Million ≈ $6.96 Million |
0.168x | -28.28% |
| 2006-12-31 | CN¥236.44 Million ≈ $34.60 Million |
CN¥55.39 Million ≈ $8.10 Million |
0.234x | +561.08% |
| 2005-12-31 | CN¥239.39 Million ≈ $35.03 Million |
CN¥8.48 Million ≈ $1.24 Million |
0.035x | +560.32% |
| 2004-12-31 | CN¥252.36 Million ≈ $36.93 Million |
CN¥1.35 Million ≈ $198.17K |
0.005x | +103.17% |
| 2003-12-31 | CN¥242.64 Million ≈ $35.51 Million |
CN¥-41.13 Million ≈ $-6.02 Million |
-0.170x | -296.91% |
| 2002-12-31 | CN¥253.20 Million ≈ $37.05 Million |
CN¥21.80 Million ≈ $3.19 Million |
0.086x | +105.99% |
| 2001-12-31 | CN¥251.63 Million ≈ $36.82 Million |
CN¥10.52 Million ≈ $1.54 Million |
0.042x | +208.63% |
| 2000-12-31 | CN¥251.29 Million ≈ $36.77 Million |
CN¥-9.67 Million ≈ $-1.41 Million |
-0.038x | -119.13% |
| 1999-12-31 | CN¥244.10 Million ≈ $35.72 Million |
CN¥49.09 Million ≈ $7.18 Million |
0.201x | +1911.55% |
| 1998-12-31 | CN¥235.71 Million ≈ $34.49 Million |
CN¥2.36 Million ≈ $344.84K |
0.010x | -- |
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. I… Read more